Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/2/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 63 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Sahota O. Reducing the risk of fractures with calcium and vitamin D. BMJ 2010;340:109-11. [Ref.ID 87576]
22.Tiene citas relacionadas Cita con resumen
The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010;340:139. [Ref.ID 87575]
23.Tiene citas relacionadas Cita con resumen
Colón-Emeric CS, Lyles KW. Should there be a fracas over FRAX and other fracture prediction tools?. Arch Intern Med 2009;169:2095. [Ref.ID 87416]
24.Tiene citas relacionadas Cita con resumen
Ensrud KE, Lui L-Y, Taylor BC, Schousboe JT, Donaldson MG, Fink HA, Cauley JA, Hillier TA, Browner WS, Cummings SR, for the Study of Osteoporotic Fractures Research Group. A comparison of prediction models for fractures in older women. Is more better?. Arch Intern Med 2009;169:2087-94. [Ref.ID 87415]
25. Cita con resumen
Cimbollek S, Quiralte J, Avila R. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs. N Engl J Med 2009;361:2197-8. [Ref.ID 87216]
26. Cita con resumen
Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:1015. [Ref.ID 86994]
27.Tiene citas relacionadas Cita con resumen
Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008;371:923-31. [Ref.ID 82403]
28.Tiene citas relacionadas Cita con resumen
Mendis S, Mohan V. Non-laboratory-based prediction of cardiovascular risk. Lancet 2008;371:878-9. [Ref.ID 82393]
29. Cita con resumen
Sosa Henríquez M, Díaz Curiel M, Díez Pérez A, Gómez Alonso C, González Macías J, Farrerons Minguella J, Filgueira Rubio J, Mellibovsky Saidler L, Nogués Solán X, Hernández Hernández D, en nombre del Grupo de Trabajo en Osteoporosis de la Sociedad Española de Medicina Interna (GTO-SEMI). Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna. Rev Clin Esp 2008;208:33-45. [Ref.ID 82144]
30. Cita con resumen
Maestri E, Spettoli D, Basevi V, Borghi F, Sanguanini A, Magrini N. La contraccezione ormonale oggi. Informazioni sui Farmaci 2007;31:36-46. [Ref.ID 80536]
31.Enlace a cita original Cita con resumen
Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, Zapata E, Bastida G, Rodrigo L, Santolaria S, Güell M, Martín de Argila C, Quintero E, Borda F, Piqué JM, on behalf of the Investigators of the Asociación Española de Gastroenterología (AEG). Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006;55:1731-8. [Ref.ID 77995]
32.Tiene citas relacionadas Cita con resumen
Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C, De Swiet M, Fletcher G, Jokinen M, Murphy D, Nelson-Piercy C, Osgood V, Robson S, Shennan A, Tuffnell A, Twaddle S, Waugh J. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005;330:576-80. [Ref.ID 73111]
33.Tiene citas relacionadas Cita con resumen
Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565-7. [Ref.ID 73107]
34.Tiene citas relacionadas Cita con resumen
Greer IA. Pre-eclampsia matters. BMJ 2005;330:549-50. [Ref.ID 73100]
35.
Amorim MR, Castilla EE, Orioli I M. Is there a familial link between Down's syndrome and neural tube defects? Population and familial survey. BMJ 2004;328:84-7. [Ref.ID 68724]
36. Cita con resumen
Buhre W, Rossaint R. Perioperative management and monitoring in anaesthesia. Lancet 2003;362:1839-46. [Ref.ID 68282]
37.Tiene citas relacionadas Cita con resumen
Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SAA, Pettinger M, Liu J, McNeeley SG, López AM, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women's Health Initiative randomized trial. JAMA 2003;290:1739-48. [Ref.ID 67706]
38.Tiene citas relacionadas Cita con resumen
Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative randomized trial. JAMA 2003;290:1729-38. [Ref.ID 67705]
39. Cita con resumen
Gimeno V, Castellsagué J, Varas C, Hopkins JS, Eaton S, Perez-Gutthann S. Gastrointestinal and cardiovascular characterization of users of COX-2 specific inhibitors. Pharmacoepidemiol Drug Saf 2003;12:S43. [Ref.ID 67112]
40.Tiene citas relacionadas Cita con resumen
Drummond G. ASCOT-LLA: questions about the benefits of atorvastatin. Lancet 2003;361:1987-8. [Ref.ID 66182]
Seleccionar todas
 
<< anterior 21 a 40 de 63 siguiente >>